Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunostimulating complexes (ISCOMs) for nasal vaccination.

K F Hu1, K Lövgren-Bengtsson, B Morein

  • 1Swedish University of Agricultural Sciences, College of Veterinary Medicine, Department of Veterinary Microbiology, Section of Virology, Box 585, BMC, S-751 23, Uppsala, Sweden. kefei.hu@bmc.uu.se

Advanced Drug Delivery Reviews
|August 23, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the humoral immune response to a multicomponent recombinant vaccine against S. aureus in healthy pregnant heifers.

Veterinary journal (London, England : 1997)·2018
Same author

Immune response and functional role of antibodies raised in heifers against a Staphylococcus aureus CP5 lysate and recombinant antigens vaccine formulated with Iscom Matrix adjuvant.

Veterinary immunology and immunopathology·2014
Same author

The ISCOM: an immunostimulating complex.

Immunology today·2014
Same author

Immune responsiveness in the neonatal period.

Journal of comparative pathology·2007
Same author

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.

Journal of medical virology·2007
Same author

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

Clinical and experimental immunology·2004
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Immunostimulating complexes (ISCOMs) are effective mucosal adjuvants, enhancing immune responses to various antigens after nasal administration. ISCOMs promote IgA and CTL responses, even in distant mucosal sites, offering a promising vaccine delivery system.

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Immunostimulating complexes (ISCOMs) are established parenteral adjuvants and delivery systems.
  • ISCOMs have demonstrated efficacy in mucosal immunization across various antigens.
  • Previous research highlighted ISCOMs' capacity to induce mucosal immunity and protection via nasal administration.

Purpose of the Study:

  • To evaluate the mucosal adjuvant activity of ISCOMs with different antigens.
  • To investigate the immune response, including IgA and CTL, following nasal ISCOM administration.
  • To explore the potential of ISCOMs for targeting remote mucosal sites and enhancing immune responses.

Main Methods:

  • Incorporation of various antigens (e.g., influenza virus, RSV, HIV-gp120) into ISCOMs.

Related Experiment Videos

  • Administration of ISCOMs via nasal route in animal models.
  • Assessment of local and distant mucosal immune responses, including IgA and systemic antibody levels.
  • Evaluation of CTL induction and cytokine dependency (IL-12 vs. IL-4).

    • Main Results:

    • Nasal ISCOM administration induced potent secretory IgA and systemic immune responses.
    • ISCOMs enhanced IgA responses to co-administered antigens (rCTB, OVA) in both local and remote mucosal sites (lungs, genital tract).
    • ISCOMs induced high serum antibody levels comparable to parenteral immunization and evoked CTL responses after nasal delivery, dependent on IL-12.

    Conclusions:

    • ISCOMs serve as potent mucosal adjuvants and delivery systems, breaking immunological tolerance.
    • Nasal administration of ISCOMs effectively induces strong local and distant mucosal immunity, including IgA and CTL responses.
    • ISCOMs offer a versatile platform for developing effective mucosal vaccines against various pathogens.